Barrett's esophagus: proton pump inhibitors and chemoprevention I.

Autor: Triadafilopoulos G; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA., Taddei A, Bechi P, Freschi G, Ringressi MN, Degli'Innocenti DR, Castiglione F, Masini E, Majewski M, Wallner G, Sarosiek J, Dillon JF, McCallum RC, Dvorak K, Goldman A, Woodland P, Sifrim D, Richter JE, Vieth M, Neumann H, Langner C, Ishimura N, Amano Y, Felix VN
Jazyk: angličtina
Zdroj: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2011 Sep; Vol. 1232, pp. 93-113.
DOI: 10.1111/j.1749-6632.2011.06047.x
Abstrakt: The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.
(© 2011 New York Academy of Sciences.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje